Seek Labs is developing a programmable rapid response therapeutic platform for target ablation that leverages CRISPR technology. The platform seeks and destroys infectious pathogens and disease-driving sequences, which enables the host to better fight diseases. The programmable CRISPR platform technology enables accelerated design, development, and deployment of programmable therapeutic products to deliver precise therapeutics rapidly and at scale. The company recently completed a preliminary in vivo trial where they demonstrated their proprietary CRISPR platform extended survival and reduced viral load in pigs infected with African Swine Fever Virus, a lethal swine disease. While research is still ongoing, Seek Labs’ flexible and streamlined approach has promise for therapeutic products across a myriad of human and veterinary diseases.